Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab maintenance versus no further treatment in relapsed CLL remission
NL-OMON34951Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival. Started Sep 2010; status: active, not recruiting.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON34951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34951.